Ocular Therapeutix CMO auto-sells 14,828 shares

Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open-market sale of 14,828 shares of common stock at a weighted average price of $8.27 per share.

Rhea-AI Filing Summary

Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open-market sale of 14,828 shares of common stock at a weighted average price of $8.27 per share. The sale was made under a pre-established durable automatic sale instruction to cover tax withholding tied to restricted stock units vesting on June 1, 2026, and was not a discretionary trade. Following this transaction, she directly holds 300,079 shares of common stock.

Insider Trade Summary 10b5-1

Net Seller: 14,828 shares

Net Sell 1 txn

Insider Waheed Nadia

Role Chief Medical Officer

Sold 14,828 shs ($123K)

Type	Security	Shares	Price	Value
Sale	Common Stock	14,828	$8.27	$123K

Holdings After Transaction: Common Stock — 300,079 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on June 1, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on June 1, 2026. The sales do not represent a discretionary trade by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2388 to $8.3000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Key Figures

Shares sold: 14,828 shares Weighted average sale price: $8.27 per share Sale price range: $8.2388–$8.3000 per share +3 more

6 metrics

Shares sold 14,828 shares Open-market sale on June 3, 2026

Weighted average sale price $8.27 per share Common stock sale

Sale price range $8.2388–$8.3000 per share Multiple transactions within this range

Shares owned after sale 300,079 shares Direct ownership following transaction

RSU vesting date June 1, 2026 Tax withholding obligation for restricted stock units

Plan adoption date June 1, 2024 Durable automatic sale instruction adoption

Key Terms

durable automatic sale instruction, sell-to-cover election, restricted stock units, weighted average price

4 terms

durable automatic sale instruction financial

"sold, pursuant to a durable automatic sale instruction adopted by the reporting person on June 1, 2024"

sell-to-cover election financial

"effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations"

restricted stock units financial

"tax withholding obligations in connection with the vesting of restricted stock units on June 1, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ocular Therapeutix (OCUL) disclose in this Form 4 for Nadia Waheed?

Ocular Therapeutix reported that Chief Medical Officer Nadia Waheed sold 14,828 shares of common stock in an open-market transaction at a weighted average price of $8.27 per share, under a pre-arranged instruction to cover tax withholding on restricted stock units vesting in 2026.

Why did Ocular Therapeutix’s CMO sell 14,828 shares of OCUL stock?

The 14,828 shares were sold pursuant to a durable automatic sale instruction to execute a sell-to-cover election. This transaction was designed to satisfy tax withholding obligations arising from the vesting of restricted stock units scheduled for June 1, 2026, rather than a discretionary portfolio decision.

At what price did Nadia Waheed’s OCUL shares sell in this Form 4 filing?

The filing reports a weighted average sale price of $8.27 per share. Footnotes explain the shares were sold in multiple transactions at prices ranging from $8.2388 to $8.3000, and detailed breakdowns are available upon request from the company, shareholders, or SEC staff.

How many Ocular Therapeutix (OCUL) shares does the CMO hold after the reported sale?

After selling 14,828 shares, Chief Medical Officer Nadia Waheed directly holds 300,079 shares of Ocular Therapeutix common stock. This post-transaction balance is disclosed in the Form 4 and reflects her remaining direct ownership following the tax-related sell-to-cover transaction.

Was the Ocular Therapeutix CMO’s OCUL stock sale a discretionary trade?

No. The Form 4 states the sale occurred under a durable automatic sale instruction adopted on June 1, 2024. It specifically notes the transactions implement a sell-to-cover election for tax withholding on restricted stock unit vesting and that the sales do not represent a discretionary trade by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waheed Nadia

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

14 CROSBY DRIVE, 3RD FLOOR

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		S(1)		14,828(1)	D	$8.27(2)	300,079	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on June 1, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on June 1, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2388 to $8.3000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Todd Anderman, Attorney-in-Fact for Nadia Waheed	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)